Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-06-07 4:15 pm Sale | 2022-05-31 | 13G | Checkmate Pharmaceuticals, Inc. CMPI | venBio Global Strategic Fund II L.P. | 0 0.000% | -2,535,158 (Position Closed) | Filing History |
| 2022-06-07 11:39 am Sale | 2022-06-02 | 13D | Checkmate Pharmaceuticals, Inc. CMPI | GARDNER LEWIS ASSET MANAGEMENT L P | 0 0.000% | -1,103,417 (Position Closed) | Filing History |
| 2022-06-03 3:01 pm Sale | 2022-05-31 | 13D | Checkmate Pharmaceuticals, Inc. CMPI | Novo Holdings A/S | 0 0.000% | -1,828,484 (Position Closed) | Filing History |
| 2022-06-03 11:40 am Purchase | 2022-05-25 | 13D | Checkmate Pharmaceuticals, Inc. CMPI | GARDNER LEWIS ASSET MANAGEMENT L P | 1,103,417 5.010% | 1,103,417 (New Position) | Filing History |
| 2022-05-11 2:57 pm Sale | 2022-05-05 | 13D | Checkmate Pharmaceuticals, Inc. CMPI | Novo Holdings A/S | 1,828,484 8.300% | -341,616 (-15.74%) | Filing History |
| 2022-05-05 4:15 pm Sale | 2022-05-03 | 13G | Checkmate Pharmaceuticals, Inc. CMPI | venBio Global Strategic Fund II L.P. | 2,535,158 11.500% | -1,138,216 (-30.99%) | Filing History |
| 2022-02-14 11:56 am Purchase | 2021-12-31 | 13G | Checkmate Pharmaceuticals, Inc. CMPI | Decheng Capital Management III (Cayman) LLC | 1,333,254 6.160% | 1,333,254 (New Position) | Filing History |
| 2022-02-14 10:16 am Sale | 2021-12-31 | 13G | Checkmate Pharmaceuticals, Inc. CMPI | CLOUGH CAPITAL PARTNERS L P | 1,137,764 5.260% | -414,562 (-26.71%) | Filing History |
| 2021-11-01 4:03 pm Unchanged | 2021-11-01 | 13D | Checkmate Pharmaceuticals, Inc. CMPI | Novo Holdings A/S | 2,170,100 10.000% | 0 (Unchanged) | Filing History |
| 2021-05-24 4:03 pm Purchase | 2021-05-07 | 13G | Checkmate Pharmaceuticals, Inc. CMPI | CLOUGH CAPITAL PARTNERS L P | 1,552,326 7.180% | 201,108 (+14.88%) | Filing History |
| 2021-02-12 2:13 pm Purchase | 2020-08-11 | 13G | Checkmate Pharmaceuticals, Inc. CMPI | Omega Fund VI L.P. | 1,335,050 6.200% | 1,335,050 (New Position) | Filing History |
| 2021-02-12 12:22 pm Purchase | 2020-12-31 | 13G | Checkmate Pharmaceuticals, Inc. CMPI | CLOUGH CAPITAL PARTNERS L P | 1,351,218 6.270% | 18,821 (+1.41%) | Filing History |
| 2020-11-10 2:54 pm Purchase | 2020-11-09 | 13G | Checkmate Pharmaceuticals, Inc. CMPI | CLOUGH CAPITAL PARTNERS L P | 1,332,397 6.220% | 1,332,397 (New Position) | Filing History |
| 2020-10-06 3:19 pm Purchase | 2020-08-11 | 13G | Checkmate Pharmaceuticals, Inc. CMPI | venBio Global Strategic Fund II L.P. | 3,673,374 17.100% | 3,673,374 (New Position) | Filing History |
| 2020-08-21 4:24 pm Purchase | 2020-08-11 | 13D | Checkmate Pharmaceuticals, Inc. CMPI | Longitude Capital Partners III LLC | 1,794,671 8.400% | 1,794,671 (New Position) | Filing History |
| 2020-08-19 11:58 am Purchase | 2020-08-11 | 13D | Checkmate Pharmaceuticals, Inc. CMPI | Sofinnova Venture Partners IX L.P. | 3,606,707 16.800% | 3,606,707 (New Position) | Filing History |
| 2020-08-18 4:29 pm Purchase | 2020-08-11 | 13G | Checkmate Pharmaceuticals, Inc. CMPI | Medicxi Growth I LP | 1,501,716 7.000% | 1,501,716 (New Position) | Filing History |
| 2020-08-13 4:47 pm Purchase | 2020-08-11 | 13D | Checkmate Pharmaceuticals, Inc. CMPI | Novo Holdings A/S | 2,170,100 10.100% | 2,170,100 (New Position) | Filing History |